Therapeutic Exosome Surface Engineering for High-Purity Affinity Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current purification methods for exosomes are inadequate in removing impurities such as contaminant proteins, DNA, and lipids, leading to heterogeneity in physicochemical properties that hinder their therapeutic efficacy due to molecular targeting, immune evasion, and controlled drug release, necessitating the development of methods for generating discrete sub-populations of exosomes with desired properties.
Innovation Solution
Utilization of newly identified surface markers like PTGFRN, BSG, IGSF2, IGSF3, IGSF8, ITGB1, ITGA4, SLC3A2, and ATP transporter proteins for affinity purification and surface engineering of exosomes, enabling selective isolation and modification to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If current purification methods are used for exosomes, then the purification process is simple and fast, but the purity of exosomes is insufficient due to inability to remove significant amounts of contaminant proteins, DNA, carbohydrates, and lipids
Solution Approach 1:
The patent introduces affinity ligands as intermediary molecules that specifically bind to exosome surface markers (such as CD9, CD63, CD81 tetraspanins or Alix, TSG101 ESCRT proteins). These ligands act as mediators between the purification system and exosomes, enabling selective capture of exosomes while leaving contaminant proteins, DNA, carbohydrates, and lipids in the supernatant, thereby achieving high purity without complex multi-step procedures
Solution Approach 2:
The patent changes the binding parameters by using specific affinity ligands that recognize and bind to unique surface markers on exosomes. By adjusting the affinity binding conditions (such as incubation time, temperature, and ligand concentration), the method achieves selective purification of exosomes based on their surface protein composition, resolving the contradiction between simplicity and purity
2Reliability
If exosomes are used for therapeutic purposes, then they offer advantages as drug delivery vehicles, but heterogeneity in their physicochemical parameters hinders molecular targeting, immune evasion, and controlled drug release
Solution Approach 1:
The patent applies local quality by specifically targeting and modifying the surface properties of exosomes through affinity ligand binding. By concentrating therapeutic agents or targeting moieties at specific locations on the exosome surface where affinity ligands bind, the method creates heterogeneous functional zones that enable precise molecular targeting while maintaining overall exosome stability and therapeutic efficacy
Solution Approach 2:
The patent segments the exosome population into discrete sub-populations based on their surface marker expression patterns. By using multiple affinity ligands targeting different surface proteins, the method divides the heterogeneous exosome population into distinct groups with uniform physicochemical properties, each suitable for specific therapeutic applications requiring consistent molecular targeting, immune evasion, or drug release characteristics
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for the production of exosomes with higher purity and controlled surface modifications, improving molecular targeting and immune evasion, thereby enhancing their therapeutic potential.
Implementation Method 1
contacting the sample with a binding agent having affinity to a target protein
Data Source
AI summary
The present invention relates to methods of preparing a therapeutic exosome using a protein newly-identified to be enriched on the surface of exosomes. Specifically, the present invention provides methods of using the proteins for affinity purification of exosomes. It also provides methods of localizing a therapeutic peptide on exosomes, and targeting exosomes to a specific organ, tissue or cell by using the proteins. The methods involve generation of surface-engineered exosomes that include one or more of the exosome proteins at higher density, or a variant or a fragment of the exosome protein.